Safety, reactogenicity, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons: A protocol for a living systematic review and meta-analysis

Author:

Ciapponi Agustín1,Berrueta Mabel1,Ballivian Jamile1,Bardach Ariel1,Mazzoni Agustina1,Anderson Steven2,Argento Fernando J.1,Bok Karin3,Comandé Daniel1,Goucher Erin4,Kampmann Beate5,Parker Edward P. K.5,Rodriguez-Cairoli Federico1,Maria Victoria Santa1,Stergachis Andy6,Voss Gerald7,Xiong Xu4,Zaraa Sabra6,Munoz Flor M.8,Karron Ruth A.9,Gottlieb Sami L.10,Buekens Pierre M.6

Affiliation:

1. Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET)

2. United States Food and Drug Administration

3. National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center

4. School of Public Health and Tropical Medicine, Tulane University

5. The Vaccine Centre, London School of Hygiene and Tropical Medicine

6. School of Pharmacy and School of Public Health, University of Washington

7. Coalition for Epidemic Preparedness Innovations

8. Baylor College of Medicine, Texas Children's Hospital

9. Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University

10. Department of Sexual and Reproductive Health and Research, World Health Organization

Abstract

Abstract Background Numerous vaccines have been evaluated and approved for coronavirus disease 2019 (COVID-19). Since pregnant persons have been excluded from most clinical trials of COVID-19 vaccines, sufficient data regarding safety of these vaccines for the pregnant persons and their fetus have rarely been available at the time of product licensure. However, as COVID-19 vaccines have been deployed, data on the safety, efficacy or effectiveness, reactogenicity, and immunogenicity of COVID-19 vaccines for pregnant persons and neonates are becoming increasingly available. A living systematic review (LSR) of the safety and effectiveness of COVID-19 vaccines for pregnant persons and newborns could provide information necessary to help guide vaccine policy decisions. Methods We aim to conduct a LSR based on biweekly searches of medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries to systematically identify relevant studies of COVID-19 vaccines for pregnant persons. Pairs of reviewers will independently select, extract data, and conduct risk of bias assessments. We will include randomized clinical trials, quasi-experimental studies, cohort, case-control, cross-sectional studies, and case reports. Primary outcomes will be the safety (i.e., impacts on obstetric and neonatal outcomes), efficacy or effectiveness of COVID-19 vaccines in pregnant persons. Secondary outcomes will be immunogenicity and reactogenicity. We will conduct paired meta-analyses, including pre-specified subgroup and sensitivity analyses, and will use the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to evaluate the certainty of evidence. Conclusion This will be the first living systematic review (LSR) and meta-analysis assessing the safety, reactogenicity, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons. An online interactive dashboard for data visualization using Microsoft Power BI will be developed to regularly update and disseminate the latest findings (an in-progress version is available at https://safeinpregnancy.org/lsr/). In addition, the findings will be disseminated through publications and presentations.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3